QIMR Berghofer-led research in collaboration with Australian oncology company Kazia Therapeutics has found that combining the drug candidate paxalisib with immunotherapy triggered a molecular epigenetic process that prevented the spread of cancer cells and overcame treatment resistance in preclinical models of triple negative breast cancer.